The complete 96-week and post-treatment follow up data from the Phase 1 monotherapy (NCT04536337) cohorts in subjects with chronic HBV infection show the continued potential of pevifoscorvir sodium to ...
They manage to slow down the progression of Huntington's disease using a gene therapy treatment called AMT 130.
On December 10, 2025 — Fondazione Telethon announced that the U.S. Food and Drug Administration (FDA) has approved the ...
TN-401 was Well Tolerated at 3E13 vg/kg dose Robust Transduction and Demonstrated Increases in PKP2 Protein Levels in First ...
Revenue -- $1.9 billion reported for the quarter, compared to prior sales cycles impacted by earlier U.S. COVID-19 vaccine ...
Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback